Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | DGAT2 | Q96PD7 | 10/20 | 0.35 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15905591 | 0.91 | ELANE (0.38) | SMN1; SMN2GLADGAT2LMNA | |
| SCHEMBL10089862 | 0.85 | DGAT2 (0.36) | SMN1; SMN2GLADGAT2LMNA | |
| SCHEMBL11928337 | 0.84 | P2RX7 (0.32) | LMNAALDH1A1 | |
| SCHEMBL10089983 | 0.84 | ELANE (0.39) | SMN1; SMN2GLADGAT2LMNA | |
| SCHEMBL12355331 | 0.83 | SLC16A3 (0.33) | — | |
| SCHEMBL11928613 | 0.83 | CNR2 (0.33) | — | |
| SCHEMBL13085376 | 0.83 | CNR1 (0.37) | — | |
| SCHEMBL317728 | 0.83 | ELANE (0.37) | SMN1; SMN2GLADGAT2LMNA | |
| SCHEMBL10089947 | 0.82 | CNR1 (0.38) | — | |
| SCHEMBL10089919 | 0.81 | ELANE (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120010249-A1 | Anthranilic diamide derivatives having cyclic side-chains | BAYER CROPSCIENCE AG (DE) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010249-A1 | Anthranilic diamide derivatives having cyclic side-chains | DDT, ADCY1, ANTXR2 | SMN1; SMN2 4084/4885GLA 1191/4885DGAT2 2025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.